Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636387 · ClinicalTrials.gov registry record
Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
A clinical trial, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- 14
- Enrollment target
NCT02636387: Clinical Trial study, sponsored by Montefiore Medical Center.
NCT02636387 is a clinical trial that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02636387 was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
Primary Outcome
To prospectively assess if the use of desmopressin in patients with sickle cell disease and nocturnal enuresis will decrease the number of nighttime episodes of enuresis by 50% after initiating DDAVP at 0.4 mg nightly dose with dose escalation as clinically indicated compared to the control group.
Interventions
- DRUG Desmopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-08-26 |
| Est. Completion | 2018-10-27 |
Why NCT02636387 stopped before completion
NCT02636387 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Desmopressin is the first listed.
NCT02636387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02636387 about?
NCT02636387 is a clinical study titled "Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease". This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
What is the current status of trial NCT02636387?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2015-08-26. Estimated completion is 2018-10-27.
What interventions are being tested in trial NCT02636387?
The interventions under investigation include: Desmopressin (DRUG).
Who is sponsoring clinical trial NCT02636387?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy